Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
ICH GUIDELINES FOR
STABILITY TESTING
Presented by-
Ankita Kawtikwar
Roll no. 504
M.Pharm (Sem-I) Seminar
Department of Pha...
WHAT IS ICH?
 International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for human use.
 brin...
NEED TO HARMONISE?
 Independent evaluation of medicinal product before
they enter the market.
 Industry becoming Global
...
INITIATION OF ICH
 - 1980: European Community
Discussions between Europe, Japan and the US
 - 1989: WHO conference of Dr...
DRUG STABILITY
 A measure of how a
pharmaceutical product
maintains its quality
attribute over a period
of time.
5
TYPES OF DRUG STABILITY
6
STABILITY TESTING
 To provide evidence on how the quality of a
drug substance or drug product varies with
time.
 Establi...
CLIMATIC ZONES
8
REGIONS AND ZONES
9
ICH GUIDELINES FOR STABILITY TESTING
10
Q1A(R2)
STABILITY TESTING OF DRUG
SUBSTANCE AND DRUG PRODUCT
11
STRESS TESTING
Helps in
 Identification of degradants
 Identification of degradation pathways
 Determination of which t...
TYPICAL STRESS CONDITIONS
13
 STRESS TESTING FOR NEVIRAPINE
14
Data from stability studies should be provided on at
least three primary batches of the active substance.
CONTAINER CLOSUR...
TESTING FREQUENCY
16
STORAGE CONDITIONS
*It is upto the applicant to decide whether long term stability
studies are performed at 25±2°C/ 60%RH±...
If significant change occurs within the first 3 months
testing at the accelerated storage condition, it is
considered unne...
In the absence of an accelerated storage condition
for drug substances intended to be stored in a freezer,
testing on a si...
 Testing of attributes that are susceptible to change during
storage and likely to influence quality , safety and/or
effi...
EVALUATION
 Should include results from physical, chemical,
biological and microbiological tests.
STATEMENT AND LABELLING...
FOR DRUG PRODUCT
SELECTION OF BATCHES
 Data from stability studies should be provided on at least
three primary batches o...
A 5% loss in water from its initial value is considered a significant change for
a product packaged in a semi-permeable co...
 If significant change occurs between 3 &6 months’
testing at the accelerated storage condition, the
proposed shelf life ...
Q1B: STABILITY TESTING: PHOTOSTABILITY TESTING OF
NEW DRUG SUBSTANCES AND PRODUCTS
A systematic approach to stability test...
PROCEDURE
26
PHOTOSTABILITY TESTING OF DRUG
SUBSTANCE
FORCED DEGRADATION
TEST
CONFIRMATORY TEST
To evaluate photosensitivity
for metho...
Q1C: STABILITY FOR NEW DOSAGE
FORMS
 NEW DOSAGE FORM
-Administration route
- New specific functionality/delivery systems
...
Q1D:BRACKETING AND MATRIXING DESIGNS
FOR STABILITY TESTING OF NEW DRUG
SUBSTANCES AND PRODUCTS
BRACKETING: The design of a...
 MATRIXING
The design of a stability schedule such that a selected subset
of the total number of possible samples for all...
ONE THIRD REDUCTION
31
Q1E: EVALUATION OF STABILITY DATA
 Presentation
 Extrapolation
 No significant change at accelerated condition (For
RT ...
THANK YOU
33
You’ve finished this document.
Download and read it offline.
Upcoming SlideShare
What to Upload to SlideShare
Next
Upcoming SlideShare
What to Upload to SlideShare
Next
Download to read offline and view in fullscreen.

Share

ICH Guidelines for stability testing

Download to read offline

ICH Guidelines for stability testing (ICH Q Guidelines)

Related Audiobooks

Free with a 30 day trial from Scribd

See all

ICH Guidelines for stability testing

  1. 1. ICH GUIDELINES FOR STABILITY TESTING Presented by- Ankita Kawtikwar Roll no. 504 M.Pharm (Sem-I) Seminar Department of Pharmaceutics Dr. D.Y.Patil Institute of Pharmaceutical and Sciences and Research, Pimpri, Pune,411018 1
  2. 2. WHAT IS ICH?  International Council for Harmonisation of Technical Requirements for Pharmaceuticals for human use.  brings together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. 2
  3. 3. NEED TO HARMONISE?  Independent evaluation of medicinal product before they enter the market.  Industry becoming Global  Duplicate test procedures Time consuming Expensive  Increasing R & D costs  Meeting public demand 3
  4. 4. INITIATION OF ICH  - 1980: European Community Discussions between Europe, Japan and the US  - 1989: WHO conference of Drug Regulatory Authorities, Paris (ICDRA)  International Federation of Pharmaceutical Manufacturers and Association(IFPMA)  - 1990: Birth of ICH at meeting hosted by European Federation of Pharmaceutical Industries (EFPIA) and Associations at Brussels Europe Japan US  Topics of Harmonisation divided into : Safety, Efficacy and Quality 4
  5. 5. DRUG STABILITY  A measure of how a pharmaceutical product maintains its quality attribute over a period of time. 5
  6. 6. TYPES OF DRUG STABILITY 6
  7. 7. STABILITY TESTING  To provide evidence on how the quality of a drug substance or drug product varies with time.  Establish shelf life for the drug product  Determine recommended storage conditions  Determine container closure system suitability 7
  8. 8. CLIMATIC ZONES 8
  9. 9. REGIONS AND ZONES 9
  10. 10. ICH GUIDELINES FOR STABILITY TESTING 10
  11. 11. Q1A(R2) STABILITY TESTING OF DRUG SUBSTANCE AND DRUG PRODUCT 11
  12. 12. STRESS TESTING Helps in  Identification of degradants  Identification of degradation pathways  Determination of which type(s) of stress affect the molecule - Photo-stability - High Temperature - Low Temperature - Oxidation - pH extremes - Water 12
  13. 13. TYPICAL STRESS CONDITIONS 13
  14. 14.  STRESS TESTING FOR NEVIRAPINE 14
  15. 15. Data from stability studies should be provided on at least three primary batches of the active substance. CONTAINER CLOSURE SYSTEM Studies should be conducted on the substance packaged in a container closure system that is the same or simulates the packaging proposed for storage and distribution. SELECTION OF BATCHES 15
  16. 16. TESTING FREQUENCY 16
  17. 17. STORAGE CONDITIONS *It is upto the applicant to decide whether long term stability studies are performed at 25±2°C/ 60%RH±5%RH or 30°C±2°C/65%±5%RH. **If 30°C±2°C/65%±5%RH is the long term condition, there is no intermediate condition. GENERAL CASE 17
  18. 18. If significant change occurs within the first 3 months testing at the accelerated storage condition, it is considered unnecessary to continue to test a drug substance through 6 months. DRUG SUBSTANCES INTENDED FOR STORAGE IN A REFRIGERATOR 18
  19. 19. In the absence of an accelerated storage condition for drug substances intended to be stored in a freezer, testing on a single batch at an elevated temperature (e.g., 5°C ± 3°C or 25°C ± 2°C) for an appropriate time period should be conducted to address the effect of short term excursions outside the proposed label storage condition, e.g., during shipping or handling. DRUG SUBSTANCES INTENDED FOR STORAGE IN A FREEZER 19
  20. 20.  Testing of attributes that are susceptible to change during storage and likely to influence quality , safety and/or efficacy.  E.g. Appearance, assay, degradation  STABILITY COMMITMENT  1. If the submission includes data from stability studies on at least three production batches, a commitment should be made to continue these studies through the proposed re- test period.  2. Fewer than three production batches, a commitment should be made to continue these studies through the proposed retest period and to place additional production batches, to a total of at least three, on long term stability studies through the proposed re-test period.  3. If no data on production batches, a commitment to place the first three production batches on long term stability studies through the proposed re-test period. SPECIFICATION 20
  21. 21. EVALUATION  Should include results from physical, chemical, biological and microbiological tests. STATEMENT AND LABELLING  Storage statement Established for labelling should be in accordance with national/regional requirement.  Re-test date -Statement based on stability evaluation -Should be displayed on the container label 21
  22. 22. FOR DRUG PRODUCT SELECTION OF BATCHES  Data from stability studies should be provided on at least three primary batches of pharmaceutical product.  Primary batches should be of same formulation and packaged in the same container closer system as proposed for marketing  Two of three batches should be at least pilot scale batches and the third one can be smaller, if justified. TESTING FREQUENCY STORAGE CONDITIONS (general case- same as that of drug substance) 22
  23. 23. A 5% loss in water from its initial value is considered a significant change for a product packaged in a semi-permeable container after an equivalent of 3 months’ storage at 40°C/NMT 25%RH.  Drug products intended for storage below -20  Stability commitment  Evaluation  Statements/Labelling DRUG PRODUCTS PACKAGED IN SEMI-PERMEABLE CONTAINERS 25%RH 23
  24. 24.  If significant change occurs between 3 &6 months’ testing at the accelerated storage condition, the proposed shelf life should be based on the real time data available from the long term storage condition. DRUG PRODUCTS INTENDED FOR STORAGE IN A REFRIGERATOR 24
  25. 25. Q1B: STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS A systematic approach to stability testing is recommended covering as appropriate studies such as: 1) Tests on the active substance 2) On exposed product outside of the immediate pack and if necessary 3) On the product in the immediate pack and if necessary 4) On the product in the marketing Light sources D65/ID65, fluorescent lamp combining visible and UV outputs, Xenon or metal halide lamp 25
  26. 26. PROCEDURE 26
  27. 27. PHOTOSTABILITY TESTING OF DRUG SUBSTANCE FORCED DEGRADATION TEST CONFIRMATORY TEST To evaluate photosensitivity for method development and/or degradation pathway elucidation Sample should be in chemically inert and transparent containers Variety of exposure conditions may be used Provide information necessary for handling, packaging and labelling If clearly photo stable and photo labile then it should be confirmed in single batch. If results are equivocal two additional batches should be conducted 27
  28. 28. Q1C: STABILITY FOR NEW DOSAGE FORMS  NEW DOSAGE FORM -Administration route - New specific functionality/delivery systems - Different dosage form  STABILITY PROTOCOL Stability protocols should follow the guidance in the principle of parent stability guideline. However a reduced stability database at submission time (e.g. 6 months accelerated and 6 months long term data from ongoing studies) may be acceptable in certain justified cases. Same active substance 28
  29. 29. Q1D:BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS BRACKETING: The design of a stability schedule such that the samples on the extremes of certain factors (e.g. Strength, container size or fill) are tested at all time points as in a full design. 29
  30. 30.  MATRIXING The design of a stability schedule such that a selected subset of the total number of possible samples for all factor combinations would be tested at specified time point. 30
  31. 31. ONE THIRD REDUCTION 31
  32. 32. Q1E: EVALUATION OF STABILITY DATA  Presentation  Extrapolation  No significant change at accelerated condition (For RT storage)  Significant change at accelerated condition(RT)  No significant change at intermediate condition (RT)  Significant change at intermediate condition(RT)  No significant change at accelerated condition(for storage in refrigerator)  Drug substances or products intended for storage in a freezer  Drug substances or products intended for storage below -20°C 32
  33. 33. THANK YOU 33
  • MahadhiShishir

    Sep. 20, 2021
  • sushmar7

    Apr. 22, 2021
  • OviyaArulmeena

    Apr. 19, 2021
  • VigneshSathyanarayan2

    Jan. 19, 2021
  • vanisri27

    Jan. 1, 2021
  • AiswaryaBabu5

    Dec. 26, 2020
  • UdaySpartan

    Dec. 24, 2020
  • ChristalFernandes

    Apr. 23, 2020
  • AmanKumar1786

    Mar. 3, 2020
  • KushiKaushi

    Jan. 29, 2020

ICH Guidelines for stability testing (ICH Q Guidelines)

Views

Total views

215

On Slideshare

0

From embeds

0

Number of embeds

0

Actions

Downloads

19

Shares

0

Comments

0

Likes

10

×